%0 Journal Article
%T 含贝达喹啉方案治疗MDR/RR-TB的安全性应用研究进展<br>Research Progress on the Safety of the Treatment of MDR/RR-TB with a Regimen Containing Bedaquiline
%A 王娅
%A 张红燕
%A 胡春扬
%A 杨芳
%A 张云桂
%J Advances in Clinical Medicine
%P 270-276
%@ 2161-8720
%D 2025
%I Hans Publishing
%R 10.12677/acm.2025.1571985
%X 贝达喹啉(Bendaquinoline, Bdq)是一种二芳基喹啉类抗结核药物&#65292;主要用于治疗耐多药结核病(MDR-TB)或利福平耐药结核病(RR-TB)。它能够有效缩短治疗周期并显著提高治疗效果&#65292;成为MDR/RR-TB患者的重要治疗选择。但是&#65292;某些患者在使用Bdq时会产生药物不良反应&#65292;上述药物反应始终是治疗过程中DR/RR-TB患者的临床难点。本综述将深入探讨Bdq的作用机制、推荐剂量、药物相互作用&#65292;临床应用以及带来的一系列不良影响&#65292;旨在为临床医生提供更安全、有效的使用Bdq的参考&#65292;帮助优化治疗方案&#65292;降低不良反应的风险。<br>Bendaquinoline (Bdq) is a diarylquinoline anti-tuberculosis drug, mainly used to treat multidrug-resistant tuberculosis (MDR-TB) or rifampicin-resistant tuberculosis (RR-TB). It can effectively shorten the treatment cycle and significantly improve the treatment effect, becoming an important treatment choice for MDR/RR-TB patients. However, some patients may experience adverse drug reactions when using Bdq, which remains a clinical challenge for DR/RR-TB patients during the treatment process. This review will delve into the mechanism of action, recommended dosage, drug interactions, clinical applications, and a series of adverse effects of Bdq, aiming to provide clinical doctors with safer and more effective references for the use of Bdq, help optimize treatment plans, and reduce the risk of adverse reactions.
%K 贝达喹啉&#65292
%K 耐多药结核病&#65292
%K 利福平耐药结核病&#65292
%K 安全性<br>Bedaquiline
%K Multidrug-Resistant Tuberculosis
%K Rifampin-Resistant Tuberculosis
%K Safety
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=118872